| A diverse range of gene products are effectors of the type I interferon antiviral response JW Schoggins, SJ Wilson, M Panis, MY Murphy, CT Jones, P Bieniasz, ... Nature 472 (7344), 481-485, 2011 | 2715 | 2011 |
| Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu SJD Neil, T Zang, PD Bieniasz Nature 451 (7177), 425-430, 2008 | 2425 | 2008 |
| Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442, 2020 | 2111 | 2020 |
| Evolution of antibody immunity to SARS-CoV-2 C Gaebler, Z Wang, JCC Lorenzi, F Muecksch, S Finkin, M Tokuyama, ... Nature 591 (7851), 639-644, 2021 | 1815 | 2021 |
| Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry MJ Evans, T von Hahn, DM Tscherne, AJ Syder, M Panis, B Wölk, ... Nature 446 (7137), 801-805, 2007 | 1682 | 2007 |
| mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Nature 592 (7855), 616-622, 2021 | 1544 | 2021 |
| Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants Y Weisblum, F Schmidt, F Zhang, J DaSilva, D Poston, JCC Lorenzi, ... elife 9, e61312, 2020 | 1535 | 2020 |
| HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress J Martin-Serrano, T Zang, PD Bieniasz Nature medicine 7 (12), 1313-1319, 2001 | 955 | 2001 |
| Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies CO Barnes, AP West, KE Huey-Tubman, MAG Hoffmann, NG Sharaf, ... Cell 182 (4), 828-842. e16, 2020 | 815 | 2020 |
| Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Z Wang, F Muecksch, D Schaefer-Babajew, S Finkin, C Viant, C Gaebler, ... Nature 595 (7867), 426-431, 2021 | 791 | 2021 |
| Vaccine breakthrough infections with SARS-CoV-2 variants E Hacisuleyman, C Hale, Y Saito, NE Blachere, M Bergh, EG Conlon, ... New England Journal of Medicine 384 (23), 2212-2218, 2021 | 790 | 2021 |
| Tetherin inhibits HIV-1 release by directly tethering virions to cells D Perez-Caballero, T Zang, A Ebrahimi, MW McNatt, DA Gregory, ... Cell 139 (3), 499-511, 2009 | 770 | 2009 |
| HIV restriction factors and mechanisms of evasion MH Malim, PD Bieniasz Cold Spring Harbor perspectives in medicine 2 (5), a006940, 2012 | 649 | 2012 |
| Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses F Schmidt, Y Weisblum, F Muecksch, HH Hoffmann, E Michailidis, ... Journal of Experimental Medicine 217 (11), 2020 | 600 | 2020 |
| HIV therapy by a combination of broadly neutralizing antibodies in humanized mice F Klein, A Halper-Stromberg, JA Horwitz, H Gruell, JF Scheid, ... Nature 492 (7427), 118-122, 2012 | 597 | 2012 |
| MX2 is an interferon-induced inhibitor of HIV-1 infection M Kane, SS Yadav, J Bitzegeio, SB Kutluay, T Zang, SJ Wilson, ... Nature 502 (7472), 563-566, 2013 | 596 | 2013 |
| Intrinsic immunity: a front-line defense against viral attack PD Bieniasz Nature immunology 5 (11), 1109-1115, 2004 | 586 | 2004 |
| Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains D Sauter, M Schindler, A Specht, WN Landford, J Münch, KA Kim, ... Cell host & microbe 6 (5), 409-421, 2009 | 521 | 2009 |
| Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors GJ Towers, T Hatziioannou, S Cowan, SP Goff, J Luban, PD Bieniasz Nature medicine 9 (9), 1138-1143, 2003 | 504 | 2003 |
| Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5α T Hatziioannou, D Perez-Caballero, A Yang, S Cowan, PD Bieniasz Proceedings of the National Academy of Sciences 101 (29), 10774-10779, 2004 | 493 | 2004 |
